Drug intelligence / Profile preview

PK101-001

Development stage: Unknown
Lead developer: Pionex Management Group

Overview

PK101-001 is a component of a fixed-dose combination anti-inflammatory drug currently being developed primarily for arthritis and osteoarthritis indications. The mechanism of action is currently undefined in public sources, and the molecule is considered a new molecular entity. PK101-001 is combined with PK101-002 in the investigational product known as PK 101 (developed by PMG Pharm/Pionex Management Group Pharm). Clinical development includes phase I studies for arthritis, and the combination PK 101 is in phase III trials for osteoarthritis. The precise active ingredient in PK101-001 is not disclosed in public databases, and no published data specify its pharmacological target or chemical nature. The larger combination (PK 101) includes a herbal extract (PG201) and celecoxib[1][3][7].

Other names: PK-101-001PK101-001PK 101-001

Beyond the preview

Go deeper on PK101-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PK101-001.

Explore the full profile